Discover the pivotal role of the **US Food and Drug Administration (FDA)** in regulating **Artificial Intelligence (AI)** in healthcare and biomedicine.
In this episode of Notebook LM, we explore the critical intersection of artificial intelligence (AI) and health care. As AI reshapes biomedicine, robust evaluation and regulation are essential to ensure its safe and effective integration into medical practice. We’ll delve into the history of the US Food and Drug Administration’s (FDA) approach to regulating AI, its potential applications in medical product development and clinical care, and the challenges posed by this transformative technology.
With nearly 1,000 AI-enabled medical devices authorized by the FDA and hundreds of drug development submissions leveraging AI, the conversation highlights the importance of coordinated, flexible regulatory frameworks. We discuss the need for transparency, postmarket performance monitoring, and specialized evaluation for large language models. Most importantly, we emphasize the role of patient health outcomes in balancing the interests of the health ecosystem—from large firms to startups.
Join us as we examine how strong oversight, led by the FDA, can foster trust and innovation, ensuring AI advances improve patient care and protect public health.
FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine
supported by:
If you like to get more intersting content please become a member or if you are already a member go to the member area directly: